1. Dynamic human gut microbiome and immune shifts during an immersive psychosocial intervention program.
- Author
-
Zhou X, Ganz AB, Rayner A, Cheng TY, Oba H, Rolnik B, Lancaster S, Lu X, Li Y, Johnson JS, Hoyd R, Spakowicz DJ, Slavich GM, and Snyder MP
- Abstract
Background: Although depression is a leading cause of disability worldwide, the pathophysiological mechanisms underlying this disorder-particularly those involving the gut microbiome-are poorly understood., Method: To investigate, we conducted a community-based observational study to explore complex associations between changes in the gut microbiome, cytokine levels, and depression symptoms in 52 participants (M
age = 49.56, SD = 13.31) receiving an immersive psychosocial intervention. A total of 142 multi-omics samples were collected from participants before, during, and three months after the nine-day inquiry-based stress reduction program., Results: Results revealed that depression was associated with both an increased presence of putatively pathogenic bacteria and reduced microbial beta-diversity. Following the intervention, we observed reductions in neuroinflammatory cytokines and improvements in several mental health indicators. Interestingly, participants with a Prevotella-dominant microbiome showed milder symptoms when depressed, along with a more resilient microbiome and more favorable inflammatory cytokine profile, including reduced levels of CXCL-1., Conclusions: These findings reveal a potentially protective link between the Prevotella-dominant microbiome and depression, as evidenced by a reduced pro-inflammatory environment and fewer depressive symptoms. These insights, coupled with observed improvements in neuroinflammatory markers and mental health from the intervention, may highlight potential avenues for microbiome-targeted therapies for managing depression., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: M.P.S. is a co-founder and scientific advisor for Crosshair Therapeutics, Exposomics, Filtricine, Fodsel, Iollo, InVu Health, January AI, Marble Therapeutics, Mirvie, Next Thought AI, Orange Street Ventures, Personalis, Protos Biologics, Qbio, RTHM, SensOmics. M.P.S. serves as a scientific advisor for Abbratech, Applied Cognition, Enovone, Jupiter Therapeutics, M3 Helium, Mitrix, Neuvivo, Onza, Sigil Biosciences, TranscribeGlass, WndrHLTH, Yuvan Research. M.P.S. is a co-founder of NiMo Therapeutics. M.P.S. is an investor and scientific advisor of R42 and Swaza. M.P.S. is an investor in Repair Biotechnologies. A.B.G. is a co-founder of Arben Ventures and Xthena Partners. B.R. is a co-founder of Arben Ventures, Enovone, and an advisor to Bexson and Northstar Care. After data collection was complete, as well as after most data analysis was completed, A.B.G. and B.R. co-founded what was formerly InquiryRx with Byron Katie, but ultimately decided not to continue the venture. Trudy Green was the 100 % owner of InquiryRx. Byron Katie lectured in Stanford BIOS 237, a class co-taught by A.B.G. and M.P.S. and spoke at the Stanford Mental Healthcare Innovations Summit. At the time of the initial publication of this article, the Academic Incubator Fund, managed by Arben Ventures, of which A.B.G. and B.R. are co-founders and managing partners, is an investor in 36 companies—namely, Bloch Quantum Imaging Solutions, Elemind Technologies, North-StarCare, Mercy BioAnalytics, Othership, Superbio.ai, Empo Health, Kelso Health, Acta Pharmaceuticals, Enovone, Superhumn, Parallel Health, Mitrix Bio, Bexson Biomedical, Allia Health, Glyphic Biotechnologies, RTHM, QBio, NextThought AI, ReMinded, Lynx Tech, Firefly VR-P, Amira Health, Imago Systems, SeeMedX, Vertility Health, OnFirm, ModoScript, Outro Health, Concha Labs, The Natural Nipple, Navan Technologies, TranscribeGlass, Dognosis, MoveJoy, and Kangaroo Bio–and an advisor to Bloch Quantum Imaging Solutions, Elemind Technologies, Allia Health, and SeeMedX. The remaining authors do not have any conflicts of interest with respect to this work., (Copyright © 2024. Published by Elsevier Inc.)- Published
- 2024
- Full Text
- View/download PDF